Medicines labeled for the same conditions
Alternatives to regorafenib
5 other medicines are given the same way (oral) and in the same FDA class as regorafenib or labeled mainly for the same use (colorectal cancer); 1 is in its class, kinase inhibitors: tucatinib; the others include 1 nucleoside metabolic inhibitor and 1 thymidine phosphorylase inhibitor (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as regorafenib?
Colorectal cancer lists all 23 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Regorafenibkinase inhibitor | this medicine | none listed | n/a | Yes | No current entry |
| Tucatinibkinase inhibitor · same class | Colorectal cancer | none listed | n/a | No | No current entry |
| Capecitabinenucleoside metabolic inhibitor | Colorectal cancer | 18 labelers | $0.456 per tablet 500 mg tablet | Yes | No current entry |
| Fruquintinib | Colorectal cancer | none listed | n/a | No | No current entry |
| Tipiracil and trifluridinethymidine phosphorylase inhibitor | Colorectal cancer | none listed | n/a | No | No current entry |
| Encorafenib | Colorectal cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Regorafenib: the full record
- label, generics, price, shortages, recalls